Literature DB >> 35332505

The value of handholding during intravitreal injections.

Deon Shaughnessy1, Sarah Powell1, Louise O'Toole2.   

Abstract

BACKGROUND: Repeated intravitreal injections (IVI) have become the therapeutic standard of care for multiple retinal conditions. Reducing discomfort and anxiety around IVIs is important to ensure ongoing patient compliance with therapy. AIMS: The study aimed to investigate if handholding during an IVI reduces patient anxiety, and to ascertain if their anxiety lessens following repeated therapy.
METHODS: Patients attending for IVIs were asked preoperatively to plot their anxiety level using the visual analogue scale for anxiety (VASA) from 0-10. They were randomised into three groups: Hand-Held-Skin-to-Skin (HHS), Hand-Held-Skin-to-Glove (HHG) and Hand-not-Held (HNH) during IVI. Post-IVI, patients were asked to recall and plot their experienced level of anxiety at the time of their first injection (First Injection Anxiety, FIA) on the 0-10 visual analogue scale for anxiety. Both hand-held cohorts were also asked their preference for handholding for future injections.
RESULTS: In total, 195 patients were surveyed: HHS, n = 67; HHG, n = 58 and HNH, n = 70. A total of 98% of respondents in both Hand-Held cohorts stated they found the intervention useful in reducing anxiety, with 97% saying they would like their hand held for subsequent IVIs. Patients' anxiety levels significantly reduced when their hand was held gloved or ungloved for IVIs (p = 0.007). IVI associated anxiety did not lessen with repeated therapy.
CONCLUSION: Patient stress levels are considerably reduced when their hand is held during IVI. Handholding is a useful intervention throughout the patient journey and not solely at the time of initiation of treatment.
© 2022. The Author(s), under exclusive licence to Royal Academy of Medicine in Ireland.

Entities:  

Keywords:  AMD; Anxiety; Handholding; Intravitreal injection

Year:  2022        PMID: 35332505     DOI: 10.1007/s11845-022-02986-z

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  23 in total

1.  Anxiety levels and perceived pain intensity during intravitreal injections.

Authors:  Ori Segal; Yael Segal-Trivitz; Arie Y Nemet; Perri Cohen; Noa Geffen; Michael Mimouni
Journal:  Acta Ophthalmol       Date:  2015-07-28       Impact factor: 3.761

2.  Reasons for discontinuation of intravitreal vascular endothelial growth factor inhibitors in neovascular age-related macular degeneration.

Authors:  Anagha Vaze; Samantha Fraser-Bell; Mark Gillies
Journal:  Retina       Date:  2014-09       Impact factor: 4.256

3.  Ranibizumab for neovascular age-related macular degeneration.

Authors:  Philip J Rosenfeld; David M Brown; Jeffrey S Heier; David S Boyer; Peter K Kaiser; Carol Y Chung; Robert Y Kim
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

4.  Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.

Authors:  Peter A Campochiaro; Jeffrey S Heier; Leonard Feiner; Sarah Gray; Namrata Saroj; Amy Chen Rundle; Wendy Yee Murahashi; Roman G Rubio
Journal:  Ophthalmology       Date:  2010-04-15       Impact factor: 12.079

5.  Ten-Year Treatment Outcomes of Neovascular Age-Related Macular Degeneration from Two Regions.

Authors:  Mark Gillies; Jennifer Arnold; Sanjeeb Bhandari; Rohan W Essex; Stephanie Young; David Squirrell; Vuong Nguyen; Daniel Barthelmes
Journal:  Am J Ophthalmol       Date:  2019-10-10       Impact factor: 5.258

6.  Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.

Authors:  Quan Dong Nguyen; David M Brown; Dennis M Marcus; David S Boyer; Sunil Patel; Leonard Feiner; Andrea Gibson; Judy Sy; Amy Chen Rundle; J Jill Hopkins; Roman G Rubio; Jason S Ehrlich
Journal:  Ophthalmology       Date:  2012-02-11       Impact factor: 12.079

7.  Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration.

Authors:  Marc C Peden; Ivan J Suñer; Mark E Hammer; W Sanderson Grizzard
Journal:  Ophthalmology       Date:  2015-01-14       Impact factor: 12.079

8.  RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia.

Authors:  Sebastian Wolf; Vilma Jurate Balciuniene; Guna Laganovska; Ugo Menchini; Kyoko Ohno-Matsui; Tarun Sharma; Tien Y Wong; Rufino Silva; Stefan Pilz; Margarita Gekkieva
Journal:  Ophthalmology       Date:  2013-12-08       Impact factor: 12.079

9.  UK Age-Related Macular Degeneration Electronic Medical Record System (AMD EMR) Users Group Report IV: Incidence of Blindness and Sight Impairment in Ranibizumab-Treated Patients.

Authors:  Robert L Johnston; Aaron Y Lee; Miranda Buckle; Richard Antcliff; Clare Bailey; Martin McKibbin; Usha Chakravarthy; Adnan Tufail
Journal:  Ophthalmology       Date:  2016-09-09       Impact factor: 12.079

10.  Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP).

Authors:  Soraya Rofagha; Robert B Bhisitkul; David S Boyer; SriniVas R Sadda; Kang Zhang
Journal:  Ophthalmology       Date:  2013-05-03       Impact factor: 12.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.